Amarillo, TX, United States
Amarillo, TX, United States

Time filter

Source Type

Zhang Y.,Laura W Bush Institute For Womens Health | Zhang Y.,University of Technology, Sydney | Leach M.J.,University of Technology, Sydney | Leach M.J.,University of South Australia | And 8 more authors.
Evidence-based Complementary and Alternative Medicine | Year: 2015

We examined the National Health Interview Survey (NHIS) 2012 to explore how US adult consumers of CAM differ by gender in terms of their sociodemographic characteristics, current health conditions, and perceived benefits of CAM. All individuals who completed the adults core interviews (N = 34,525) were included. CAM use, major sociodemographic variables, perceived benefits of using CAM, and top ten reported health conditions for which CAM was used were selected and analyzed by Stata. Findings revealed that 29.6% (n = 10,181) reported having used at least one form of CAM in the previous 12 months. Compared to male CAM users, female CAM users were more likely to have a bachelor degree, to be divorced/separated or widowed, and less likely to earn $75,000 or more. Back pain/problem was the most common problem reported by both male and female CAM users (32.2% and 22.6%, resp.). A higher proportion of female CAM users reported using CAM for perceived benefits such as general wellness or general disease prevention. This paper provides foundation information regarding gender differences in CAM use and is a platform for further in-depth examination into how and why males and females differ in their reasons for CAM use. © 2015 Yan Zhang et al.


Chiriva-Internati M.,Texas Tech University Health Sciences Center | Chiriva-Internati M.,Kiromic Inc. | Chiriva-Internati M.,Laura W Bush Institute For Womens Health | Mirandola L.,Texas Tech University Health Sciences Center | And 14 more authors.
Journal of Immunotherapy | Year: 2011

Despite recent improvements in standard pharmacologic treatments of multiple myeloma (MM), immunotherapy may prove to be more effective due to its higher specificity and lower toxicity. A novel cancer/testis antigen, ropporin, is a testis-specific protein localized in the sperm flagella. Comparing ropporin expression in healthy and MM samples, we did not detect ropporin expression in the normal tissues, but positive signals were found in 44% of the MM primary samples. The immunogenicity of ropporin was confirmed by the presence of specific antibodies detected by enzyme-linked immunosorbent assay in patients serum. Our results show that ropporin is a novel cancer/testis antigen for MM. Except for in the testis, an immune privileged site, ropporin was not expressed in normal tissues, but was present in MM cell lines and patients samples. Noteworthy, we show for the first time that ropporin was present at the cell surface of MM plasma cells. We suggest that ropporin is a promising target for MM immunotherapy, as we were able to generate human leukocyte antigen class I-restricted cytotoxic lymphocytes able to kill autologous MM cells. © 2011 by Lippincott Williams & Wilkins.


Mirandola L.,TTUHSC | Mirandola L.,Laura W Bush Institute For Womens Health | Yu Y.,TTUHSC | Cannon M.J.,University of Arkansas for Medical Sciences | And 13 more authors.
Gynecologic Oncology | Year: 2014

Objective. Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3. Methods. We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested. Result. We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients. Conclusions. Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer. © 2014 Elsevier Inc. All rights reserved.


Pandey A.,Texas Tech University Health Sciences Center | Kurup A.,University of California at Irvine | Shrivastava A.,Texas Tech University Health Sciences Center | Radhi S.,Texas Tech University Health Sciences Center | And 20 more authors.
International Reviews of Immunology | Year: 2012

Breast cancer remains one of the leading causes of death among women across the world. The last few decades have seen significant reduction in mortality owing to earlier detection and better adjuvant treatments that were developed based on clinical staging and morphological features. As these treatments have evolved, the heterogeneity of breast cancer poses a new challenge, since there is no standard gold-therapy suitable for all tumors of the mammary gland. Therefore, contemporary management and research efforts are directed toward specific prognostic and predictive molecular signatures that can guide targeted individualized therapy. The goal of ongoing research in this field is to identify specific molecular targets for developing novel therapeutic approaches. These targets can also serve to improve screening of breast cancer. This review focuses on the role of cancer testis antigens (CTAs) in breast carcinogenesis and explores the potential for development of targeted screening and therapeutic approaches. Normally found in the testes, these antigens are highly correlative with cancers of the breast, skin, and ovaries. These implications have been further corroborated through uncovering the interaction of CTAs with genes and proteins involved in tumor suppression and homeostasis like p53. There is some evidence that these genes can be targeted for early detection in addition to being candidates for cancer immunotherapy. © 2012 Informa Healthcare USA, Inc.


Chiriva-Internati M.,Texas Tech University Health Sciences Center | Chiriva-Internati M.,Kiromic Inc. | Chiriva-Internati M.,Laura W Bush Institute For Womens Health | Pandey A.,Texas Tech University Health Sciences Center | And 11 more authors.
International Reviews of Immunology | Year: 2012

Lung cancer is the main cause of cancer mortality worldwide. This is mainly due to the fact that it is diagnosed in advanced stage patients, which are no more surgically curable. Consequently, searching for novel treatments and new modalities for early diagnosis offers great promise to improve the clinical outcome. Recently, a new group of antigens, the cancer testis antigens, have been described as possible early diagnostic tools and therapeutic targets in cancer therapy.This review will report emerging evidences of cancer testis antigens deregulation in lung cancer and explore the state of the art of their currently known role and potential as markers for early diagnosis and disease progression and targets of an immunotherapeutic approach aiming to improve the cure rate of this tumor. © 2012 Informa Healthcare USA, Inc.


Arnaboldi F.,University of Milan | Menon A.,University of Milan | Menegola E.,University of Milan | Di Renzo F.,University of Milan | And 10 more authors.
International Reviews of Immunology | Year: 2014

Sperm protein 17 (Sp17) was originally identified in the flagellum of spermatozoa and subsequently included in the subfamily of tumor-associated antigens known as cancer-testes antigens (CTA). Sp17 has been associated with the motility and migratory capacity in tumor cells, representing a link between gene expression patterns in germinal and tumor cells of different histological origins. Here we review the relevance of Sp17 expression in the mouse embryo and cancerous tissues, and present additional data demonstrating Sp17 complex expression pattern in this murine model. The expression of Sp17 in embryonic as well as adult neoplastic cells, but not normal tissues, suggests this protein should be considered an "oncofetal antigen." Further investigations are necessary to elucidate the mechanisms and functional significance of Sp17 aberrant expression in human adult cells and its implication in the pathobiology of cancer. © 2014 Informa Healthcare USA, Inc.


Mirandola L.,Texas Tech University | Mirandola L.,Laura W Bush Institute For Womens Health | Figueroa J.A.,Texas Tech University | Figueroa J.A.,Kiromic Inc. | And 14 more authors.
Oncotarget | Year: 2015

Lung cancer is the leading cause of cancer deaths in both genders worldwide, with an incidence only second to prostate cancer in men and breast cancer in women. The lethality of the disease highlights the urgent need for innovative therapeutic options. Immunotherapy can afford efficient and specific targeting of tumor cells, improving efficacy and reducing the side effects of current therapies. We have previously reported the aberrant expression of cancer/testis antigens (CTAs) in tumors of unrelated histological origin. In this study we investigated the expression and immunogenicity of the CTAs, Sperm Protein 17 (SP17), A-kinase anchor protein 4 (AKAP4) and Pituitary Tumor Transforming Gene 1 (PTTG1) in human non-small cell lung cancer (NSCLC) cell lines and primary tumors. We found that SP17, AKAP4 and PTTG1 are aberrantly expressed in cancer samples, compared to normal lung cell lines and tissues. We established the immunogenicity of these CTAs by measuring CTA-specific autoantibodies in patients' sera and generating CTA-specific autologous cytotoxic lymphocytes from patients' peripheral blood mononuclear cells. Our results provide proof of principle that the CTAs SP17/AKAP4/PTTG1 are expressed in both human NSCLC cell lines and primary tumors and can elicit an immunogenic response in lung cancer patients.


Mirandola L.,Texas Tech University | Mirandola L.,Laura W Bush Institute For Womens Health | Nguyen D.D.,Texas Tech University | Nguyen D.D.,Laura W Bush Institute For Womens Health | And 14 more authors.
International Reviews of Immunology | Year: 2014

Here we review the role of Galectins in the molecular pathogenesis of multiple myeloma and ovarian cancer, with a special focus on Glectin-3. Multiple myeloma is the second most common hematologic malignancy worldwide. Because the pathogenesis of multiple myeloma is still incompletely understood, there is no ultimately effective cure, and this cancer results fatal. Ovarian cancer is the most lethal gynecologic malignancy worldwide. Due to the lack of screening techniques for early detection, patients are mostly diagnosed with advanced disease, which results ultimately fatal. Multiple myeloma and ovarian cancer have different biologies, but they share a strong dependence on adhesion with extracellular matrix and other cells. Galectin-3 plays a key role in regulating such adhesive abilities of tumor cells. Here we discuss the outcomes and possible mechanism of action of a truncated, dominant negative form of Galectin-3, Galectin-3C, in these malignancies. Overall, we report that Galectin-3C is a promising new compound for effective adjuvant therapies in advanced, refractory multiple myeloma and ovarian cancer. © 2014 Informa Healthcare USA, Inc.


Zhang Y.,Texas Tech University Health Sciences Center | Zhang Y.,Laura W Bush Institute For Womens Health | Peck K.,Texas Tech University Health Sciences Center | Spalding M.,Texas Tech University Health Sciences Center | And 3 more authors.
Patient Education and Counseling | Year: 2012

Objective: To compare patients' complementary and alternative medicine (CAM) use and physicians' familiarity with certain CAM modalities in the same setting and to assess patient-provider dialogue about patients' CAM use. Methods: An observational survey study with convenience sampling at ambulatory family medicine clinics in two Texas cities. A total of 69 healthcare providers and 468 patients completed the surveys. Patients' surveys assessed use of 27 CAM therapies, perception of CAM use and interaction with providers. Providers' survey assessed perception and attitude toward CAM use. Results: CAM modalities most used by the patients are not those modalities that providers best understood. Of the 330 patients (70%) who responded to the relevant questions about discussing CAM, 44.5% reported never having discussed CAM use with their providers. Binomial logistic regression revealed no link between age, gender or ethnicity for discussing CAM with providers. College-educated patients (adjust OR = 2.8, 95%CI = 1.3-6.0) and US citizens were both about three times more likely to discuss CAM than their counterparts. Conclusion: Lack of knowledge and unfamiliarity with CAM modalities might prevent important patient-provider discussions. Practice implications: Providers should use existing resources and encourage a bilateral dialogue that involves transferring of information and assisting patients in decisions making about CAM use and health care. © 2012 Elsevier Ireland Ltd.


Cobos C.,Texas Tech University | Figueroa J.A.,Texas Tech University | Figueroa J.A.,Laura W Bush Institute For Womens Health | Figueroa J.A.,Kiromic LLC | And 23 more authors.
International Reviews of Immunology | Year: 2014

Over the past 30 years, human papilloma virus (HPV) has been shown to play a role in the development of various cancers. Most notably, HPV has been linked to malignant progression in neoplasms of the anogenital region. However, high-risk HPV has also been suggested to play a significant role in the development of cancers in other anatomic locations, such as the head and neck, lung, breast and bladder. In 2006, the first vaccine for HPV, Gardasil, was approved for the prevention of subtypes 6, 11, 16 and 18. A few years later, Cevarix was approved for the prevention of subtypes 16 and 18, the HPV subtypes most frequently implicated in malignant progression. Although increased awareness and vaccination could drastically decrease the incidence of HPV-positive cancers, these approaches do not benefit patients who have already contracted HPV and developed cancer as a result. For this reason, researchers need to continue developing treatment modalities, such as targeted immunotherapies, for HPV-positive lesions. Here, we review the potential evidence linking HPV infection with the development of non-anogenital cancers and the potential role of immunotherapy in the prevention and eradication of HPV infection and its oncogenic sequela. © 2014 Informa Healthcare USA, Inc.

Loading Laura W Bush Institute For Womens Health collaborators
Loading Laura W Bush Institute For Womens Health collaborators